More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Amgen said Tuesday that the Food and Drug Administration has ordered a hold on a study of the company’s early-stage obesity candidate, another potential setback in the company’s efforts to ...

Kennedy possibly to follow at the Department of Health and Human Services, it’s hard to say what’s in store for the Food and Drug Administration ... the fight against obesity — would ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Medicare must recognize obesity as a chronic disease and provide coverage for the treatments that can help those who struggle ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug ... didn’t say why or when the US Food and Drug Administration placed the trial of AMG-513 on clinical ...